Neutropenia and efficacy outcomes in patients with refractory mCRC: A post-hoc analysis of the phase III SUNLIGHT trial

被引：0
|
作者：
Prager, G. [1 ]
Tabernero, J. [2 ]
Fakih, M. [3 ]
Ciardiello, F. [4 ]
Van Cutsem, E. [5 ]
Roby, L. [6 ]
Yao, W. [7 ]
Choucair, E. [8 ]
Taieb, J. [9 ]
机构：
[1] Univ Kliniken MedUni Wien AKH Wien, Dept Med 1, Vienna, Austria
[2] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[3] City Hope Comprehens Canc Ctr, Med Oncol & Therapeut Res, Duarte, CA USA
[4] Univ Campania Luigi Vanvitelli, Dipartimento Med Precis, Naples, Italy
[5] UZ Leuven Univ Hosp Leuven, Digest Oncol Dept, Campus Gasthuisberg, Leuven, Belgium
[6] IRIS, Dept Oncol, Suresnes, France
[7] Servier Pharmaceut, Dept Clin Res, Boston, MA USA
[8] Lab Servier SAS, Med Affairs, Suresnes, France
[9] Hop European George Pompidou, Gastroenterol & Digest Oncol Dept, Paris, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.046
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
35P
引用
收藏
页码：S18 / S19
页数：2
相关论文
共 50 条
  • [1] Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
    Tabernero, J.
    Prager, G.
    Fakih, M.
    Ciardiello, F.
    Van Cutsem, E.
    Elez Fernandez, M. E.
    Cruz, F. J. S. M.
    Wyrwicz, L. S.
    Stroyakovskiy, D.
    Papai, Z.
    Martinelli, E.
    Salvatore, L.
    Poureau, P. G.
    Liposits, G.
    Cremolini, C.
    Modest, D. P.
    Causse-Amellal, N.
    Roby, L.
    Skanji, D.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S440 - S441
  • [2] Efficacy Of Rituximab In Patients With Refractory Lupus Nephritis, a Post-Hoc Analysis From Phase II Trial In Japan.
    Tanaka, Yoshiya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Miyasaka, Nobuyuki
    Sumida, Takayuki
    Mimori, Tsuneyo
    Koike, Takao
    Endo, Kazuhiro
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S253 - S254
  • [3] A post-hoc health-related quality of life (HRQoL) analysis of patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.
    Chang, Jane
    Odom, Dawn
    Radder, Christina
    Kappeler, Christian
    Xu, Rui-hua
    Qin, Shukui
    Kim, Tae Won
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial
    Kulkarni, Tejaswini
    Newton, Chad A.
    Gupta, Sachin
    Samara, Katerina
    Bernstein, Elana J.
    PULMONARY THERAPY, 2024, 10 (03) : 331 - 346
  • [5] Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial
    Constantin, Arnaud
    Caporali, Roberto
    Edwards, Christopher J.
    Fonseca, Joao Eurico
    Iannone, Florenzo
    Keystone, Edward
    Schulze-Koops, Hendrik
    Kwon, Taek
    Kim, Seungmin
    Yoon, SangWook
    Kim, Dong-Hyeon
    Park, Gahee
    Yoo, Dae Hyun
    RHEUMATOLOGY, 2023, 62 (08) : 2838 - 2844
  • [6] Febuxostat and renal outcomes: post-hoc analysis of a randomized trial
    Kohagura, Kentaro
    Kojima, Sunao
    Uchiyama, Kazuaki
    Yokota, Naoto
    Tokutake, Eiichi
    Wakasa, Yutaka
    Hiramitsu, Shinya
    Waki, Masako
    Jinnouchi, Hideaki
    Kakuda, Hirokazu
    Hayashi, Takahiro
    Kawai, Naoki
    Sugawara, Masahiro
    Mori, Hisao
    Tsujita, Kenichi
    Matsui, Kunihiko
    Hisatome, Ichiro
    Ohya, Yusuke
    Kimura, Kazuo
    Saito, Yoshihiko
    Ogawa, Hisao
    HYPERTENSION RESEARCH, 2023, 46 (06) : 1417 - 1422
  • [7] Febuxostat and renal outcomes: post-hoc analysis of a randomized trial
    Kentaro Kohagura
    Sunao Kojima
    Kazuaki Uchiyama
    Naoto Yokota
    Eiichi Tokutake
    Yutaka Wakasa
    Shinya Hiramitsu
    Masako Waki
    Hideaki Jinnouchi
    Hirokazu Kakuda
    Takahiro Hayashi
    Naoki Kawai
    Masahiro Sugawara
    Hisao Mori
    Kenichi Tsujita
    Kunihiko Matsui
    Ichiro Hisatome
    Yusuke Ohya
    Kazuo Kimura
    Yoshihiko Saito
    Hisao Ogawa
    Hypertension Research, 2023, 46 : 1417 - 1422
  • [8] POST-HOC ANALYSIS FROM A PHASE III TRIAL ASSESSING THE SAFETY AND EFFICACY OF RIX-FP IN PREVIOUSLY TREATED ADOLESCENT PATIENTS WITH HAEMOPHILIA B
    Alvarez Roman, M. T.
    Drelich, D. A.
    Seifert, W.
    Castaman, G.
    HAEMOPHILIA, 2023, 29 : 41 - 42
  • [9] BARICITINIB EFFICACY IN MODERATE RHEUMATOID ARTHRITIS - A POST-HOC ANALYSIS FROM TWO PHASE III TRIALS
    Kirkham, Bruce W.
    Nikiphorou, Elena
    Edwards, Christopher J.
    Sheesh, Mohamed
    Haladyj, Ewa
    Gerwien, Jens
    Zaremba-Pechmann, Liliana
    Taylor, Peter C.
    RHEUMATOLOGY, 2023, 62
  • [10] Lixisenatide and renal outcomes in patients with type 2 diabetes: a post-hoc analysis of the ELIXA trial
    Muskiet, M. H. A.
    Heerspink, H. J. L.
    Tonneijck, L.
    Huang, Y.
    Liu, M.
    Saremi, A.
    van Raalte, D. H.
    DIABETOLOGIA, 2018, 61 : S40 - S40
12345